Separate teams at the University of California, San Francisco and Pfizer have evidence that blocking Il-7 signaling in mice can arrest the autoimmune activity behind type 1 diabetes. Whether the findings will translate to the clinic depends on whether the cytokine has the same effects on helper T cell activity in mice and humans.